{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:55:07Z","timestamp":1793058907134,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"\n Importance<\/jats:title>\n Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to anthracycline use.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To test whether atorvastatin is associated with a reduction in the proportion of patients with lymphoma receiving anthracyclines who develop cardiac dysfunction.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Double-blind randomized clinical trial conducted at 9 academic medical centers in the US and Canada among 300 patients with lymphoma who were scheduled to receive anthracycline-based chemotherapy. Enrollment occurred between January 25, 2017, and September 10, 2021, with final follow-up on October 10, 2022.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized to receive atorvastatin, 40 mg\/d (n\u2009=\u2009150), or placebo (n\u2009=\u2009150) for 12 months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the proportion of participants with an absolute decline in left ventricular ejection fraction (LVEF) of \u226510% from prior to chemotherapy to a final value of &amp;lt;55% over 12 months. A secondary outcome was the proportion of participants with an absolute decline in LVEF of \u22655% from prior to chemotherapy to a final value of &amp;lt;55% over 12 months.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 300 participants randomized (mean age, 50 [SD, 17] years; 142 women [47%]), 286 (95%) completed the trial. Among the entire cohort, the baseline mean LVEF was 63% (SD, 4.6%) and the follow-up LVEF was 58% (SD, 5.7%). Study drug adherence was noted in 91% of participants. At 12-month follow-up, 46 (15%) had a decline in LVEF of 10% or greater from prior to chemotherapy to a final value of less than 55%. The incidence of the primary end point was 9% (13\/150) in the atorvastatin group and 22% (33\/150) in the placebo group (\n P<\/jats:italic>\n \u2009=\u2009.002). The odds of a 10% or greater decline in LVEF to a final value of less than 55% after anthracycline treatment was almost 3 times greater for participants randomized to placebo compared with those randomized to atorvastatin (odds ratio, 2.9; 95% CI, 1.4-6.4). Compared with placebo, atorvastatin also reduced the incidence of the secondary end point (13% vs 29%;\n P<\/jats:italic>\n \u2009=\u2009.001). There were 13 adjudicated heart failure events (4%) over 24 months of follow-up. There was no difference in the rates of incident heart failure between study groups (3% with atorvastatin, 6% with placebo;\n P<\/jats:italic>\n \u2009=\u2009.26). The number of serious related adverse events was low and similar between groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among patients with lymphoma treated with anthracycline-based chemotherapy, atorvastatin reduced the incidence of cardiac dysfunction. This finding may support the use of atorvastatin in patients with lymphoma at high risk of cardiac dysfunction due to anthracycline use.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02943590<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.11887","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:18:59Z","timestamp":1691493539000},"page":"528","source":"Crossref","is-referenced-by-count":222,"title":["Atorvastatin for Anthracycline-Associated Cardiac Dysfunction"],"prefix":"10.1001","volume":"330","author":[{"given":"Tomas G.","family":"Neilan","sequence":"first","affiliation":[{"name":"Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Quinaglia","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Onoue","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed S.","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia D.","family":"Drobni","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Gilman","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius C.","family":"Heemelaar","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Brahmbhatt","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jor Sam","family":"Ho","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supraja","family":"Sama","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim P.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferey A.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin I.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"Soumerai","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchi","family":"Han","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb S.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"Lacasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Landsburg","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nasta","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Cardiology Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jerosch-Herold","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqi","family":"Hua","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Heart Failure Trials, Baim Institute for Clinical Research, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negareh","family":"Mousavi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, McGill University Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Scherrer-Crosbie","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"41","key":"joi230077r1","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"joi230077r2","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"joi230077r3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/annonc\/mdg070","article-title":"Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin\u2019s lymphoma.","volume":"14","author":"Limat","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"joi230077r4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice.","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"joi230077r5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13105-013-0240-0","article-title":"Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice.","volume":"69","author":"Ramanjaneyulu","year":"2013","journal-title":"J Physiol Biochem"},{"issue":"2","key":"joi230077r6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score\u2013matched cohort study.","volume":"10","author":"Abdel-Qadir","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"joi230077r7","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"joi230077r8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"joi230077r9","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment.","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"issue":"20","key":"joi230077r10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"joi230077r11","doi-asserted-by":"publisher","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician.","volume":"13","author":"Perez","year":"2019","journal-title":"Clin Med Insights Cardiol"},{"issue":"4","key":"joi230077r12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy.","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"joi230077r13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX Registry.","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"joi230077r14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"joi230077r15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"joi230077r16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"joi230077r17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"joi230077r18","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"14","key":"joi230077r19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease.","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"joi230077r20","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies).","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"joi230077r21","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"joi230077r22","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial.","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"issue":"20","key":"joi230077r23","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial.","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"joi230077r24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM197902083000603","article-title":"Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.","volume":"300","author":"Alexander","year":"1979","journal-title":"N Engl J Med"},{"issue":"3","key":"joi230077r25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy.","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"issue":"2","key":"joi230077r26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/cancers15020512","article-title":"Natural progression of left ventricular function following anthracyclines without cardioprotective therapy: a systematic review and meta-analysis.","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"joi230077r27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/15376516.2012.678406","article-title":"Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats.","volume":"22","author":"Kim","year":"2012","journal-title":"Toxicol Mech Methods"},{"issue":"11","key":"joi230077r28","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity.","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"issue":"12","key":"joi230077r29","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.bbamcr.2013.08.016","article-title":"DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.","volume":"1833","author":"Wartlick","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"joi230077r30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2009.23.4245","article-title":"Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.","volume":"28","author":"Nowakowski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"joi230077r31","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/annonc\/mdp490","article-title":"Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.","volume":"21","author":"Ennishi","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"joi230077r32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.44","article-title":"HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.","volume":"4","author":"Qi","year":"2013","journal-title":"Cell Death Dis"},{"issue":"14","key":"joi230077r33","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1073\/pnas.0305149101","article-title":"Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.","volume":"101","author":"Katano","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"joi230077r34","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1080\/10428194.2021.2020782","article-title":"Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.","volume":"63","author":"Gouni","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2807988\/jama_neilan_2023_oi_230077_1691423426.14496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:19:03Z","timestamp":1691493543000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2807988"}},"subtitle":["The STOP-CA Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.11887","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}